Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The Western Canadian Gastrointestinal Cancer Consensus Conference (WC-5) convened virtually on 10 February 2021. The WC-5 is an interactive multidisciplinary conference attended by health care professionals from across Western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba) who are involved in the care of patients with gastrointestinal cancer. Surgical, medical, and radiation oncologists; pathologists; radiologists; and allied health care professionals participated in presentation and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of hepatocellular cancer (HCC). Recommendations have been made for the transition from local to systemic therapy and the optimal sequencing of systemic regimens in the management of HCC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628771 | PMC |
| http://dx.doi.org/10.3390/curroncol28060367 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: Short-term outcomes of laparoscopic D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in distal gastric cancer patients with high body mass index.
BMC Cancer
September 2025
Department of Gastrointestinal Surgery, Affiliated Hospital of Chengde Medical University, No. 36 Nanyingzi Street, Chengde, Hebei, 067000, China.
Segmental analysis of esophageal and gastric fundus microbiome diversity in reflux esophagitis.
Folia Microbiol (Praha)
September 2025
Department of Gastroenterology, Chongqing University Cancer Hospital, Chongqing, China.
Microbiome dysbiosis in reflux esophagitis has been extensively studied. However, limited research has examined microbiota across different segments of the upper gastrointestinal tract in reflux esophagitis. In this study, we investigated microbial alterations in three esophageal segments (upper, middle, and lower) and the gastric fundus of reflux esophagitis patients and healthy controls.
View Article and Find Full Text PDFClinical features of Barrett's mucosa arising in the remnant esophagus after subtotal esophagectomy and esophago-gastric anastomosis for esophageal cancer.
Esophagus
September 2025
Department of Upper Gastrointestinal Surgery, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Shimotsugagun, Tochigi, 321-0293, Japan.
Background: Barrett's mucosa in the remnant esophagus (BMRE) is often identified after gastric pull-up reconstruction after esophagectomy. This study aimed to determine the clinical characteristics of BMRE and the factors that affect the development of BMRE.
Methods: The characteristics of BMRE and factors affecting its occurrence were studied in patients with subtotal esophagectomy and gastric pull-up reconstruction who survived at least 3 years after esophageal cancer surgery and who were evaluated by endoscopy.
Immune checkpoint inhibitors combined with chemotherapy in conversion therapy for stage IV gastric cancer: a multicenter retrospective cohort study.
Cancer Immunol Immunother
September 2025
Department of Gastric Surgery, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Hangzhou, 310022, Zhejiang, China.
Objectives: To evaluate the efficacy of combining PD-1 inhibitors with chemotherapy in conversion therapy for patients with stage IV gastric cancer and to determine the populations most likely to benefit from this regimen.
Methods: Data from patients with stage IV gastric cancer who received conversion therapy with PD-1 inhibitors combined with chemotherapy between January 2018 and December 2022 at multiple centers were retrospectively reviewed. Patients who underwent conversion surgery were categorized into a surgery group, while those who did not were placed into a palliative group.
A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2.
Nat Biotechnol
September 2025
Key Laboratory of RNA Innovation, Science and Engineering, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China.
Targeted protein degraders hold potential as therapeutic agents to target conventionally 'undruggable' proteins. Here, we develop a high-throughput screen, DEath FUSion Escaper (DEFUSE), to identify small-molecule protein degraders. By conjugating the protein of interest to a fast-acting triggerable death protein, this approach translates target protein degradation into a cell survival phenotype to illustrate the presence of degraders.
View Article and Find Full Text PDF